

COVID-19 Weekly Epidemiological Update

Edition 142 published 11 May 2023

In this edition:

- Global overview
- SARS-CoV-2 variants of interest and variants under monitoring
- Vaccine effectiveness of primary series and booster vaccination against Omicron and its descendant lineages
- WHO regional overviews
- Hospitalizations and ICU admissions
- Summary of the Monthly Operational Update

Global overview

Data as of 7 May 2023

Globally, over 2.7 million new cases and over 17 000 deaths were reported in the last 28 days (10 April to 7 May 2023), a decrease of 14% and 17%, respectively, compared to the previous 28 days (13 March to 9 April 2023) (Figure 1, Table 1). The picture is mixed at the regional level, with increases in reported cases seen in the South-East Asia and Western Pacific regions and decreases in other regions. As of 7 May 2023, over 765 million confirmed cases and over 6.9 million deaths have been reported globally.

Reported COVID-19 cases are underestimates as shown by prevalence surveys.^{1–4} This is partly due to the reductions in testing and delays in reporting in many countries. Data presented in this report are therefore incomplete and should be interpreted with caution. Additionally, data from previous weeks are continuously being updated to incorporate retrospective changes in reported COVID-19 cases and deaths made by countries.

We present changes in epidemiological trends using a 28-day interval. This wider time window helps to account for delays in reporting, smooth out weekly fluctuations in case numbers, and continue to provide a clear picture of where the pandemic is accelerating or decelerating. Disaggregated data are still accessible on the WHO COVID-19 dashboard, where the full dataset is available for download.




Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 7 May 2023**

At the regional level, the number of newly reported 28-day cases decreased across four of the six WHO regions: the European Region (-38%), the Region of the Americas (-35%), the African Region (-25%), and the Eastern Mediterranean Region (-24%); while cases increased in two WHO regions: the Western Pacific Region (+35%), and the South-East Asia Region (+223%). The number of newly reported 28-day deaths decreased or remained stable across four regions: the African Region (-50%), the European Region (-41%), the Western Pacific Region(-33%), and the Eastern Mediterranean Region (+1%); while deaths increased in two WHO regions: the Region of the Americas (+9%) and the South-East Asia Region (+281%).

At the country level, the highest numbers of new 28-day cases were reported from the United States of America (366 173 new cases; -35%), the Republic of Korea (363 691 new cases; +32%), Japan (262 145 new cases; +36%), India (213 014 new cases; +222%), and France (173 375 new cases; -19%). The highest numbers of new 28-day deaths were reported from the United States of America (4680 new deaths; -36%), Brazil (1277 new deaths; +2%), the Russian Federation (955 new deaths; -3%), France (944 new deaths; +39%), and India (715 new deaths; +289%).

WHO Region	New cases in last 28 days (%)	Change in new cases in last 28 days *	Cumulative cases (%)	New deaths in last 28 days (%)	Change in new deaths in last 28 days *	Cumulative deaths (%)
Western Pacific	975 488	35%	203 126 109	1 387	-33%	411 080
	(36%)	5570	(27%)	(8%)	-3370	(6%)
Europe	800 615	-38%	276 123 761	6 345	-41%	2 233 349
	(29%)	-30/0	(36%)	(37%)	-41/0	(32%)
Americas	647 270	-35%	192 581 201	7 483	9%	2 950 808
	(24%)	-55%	(25%)	(44%)	9%	(43%)
South-East Asia	258 500	223%	61 113 283	1 178	281%	805 395
	(9%)	223%	(8%)	(7%)	281%	(12%)
Eastern	40 047	2.40/	23 362 519	707	10/	351 092
Mediterranean	(1%)	-24%	(3%)	(4%)	1%	(5%)
Africa	7 408	-25%	9 527 473	12	F.00/	175 351
	(<1%)	-25%	(1%)	(<1%)	-50%	(3%)
Global	2 729 328	1 / 0/	765 835 110	17 112	170/	6 927 088
	(100%)	-14%	(100%)	(100%)	-17%	(100%)

Table 1. Newly reported and cumulative COVID-19 confirmed cases and deaths, by WHO Region, as of 7 May 2023**

*Percent change in the number of newly confirmed cases/deaths in the past 28 days, compared to 28 days prior. Data from previous weeks are updated continuously with adjustments received from countries.

**See Annex 1: Data, table, and figure notes

The latest data and other updates on COVID-19, please see:

- WHO COVID-19 Dashboard •
- WHO Monthly Operational Update and past editions of the Weekly Epidemiological Update on COVID-19
- WHO COVID-19 detailed surveillance data dashboard
- WHO COVID-19 policy briefs




Figure 2. Percentage change in confirmed COVID-19 cases over the last 28 days relative to the previous 28 days, as of 7 May 2023**

**See Annex 1: Data, table, and figure notes




Figure 3. Percentage change in confirmed COVID-19 deaths over the last 28 days relative to the previous 28 days, as of 7 May 2023**

**See Annex 1: Data, table, and figure notes

SARS-CoV-2 variants of interest and variants under monitoring

Geographic spread and prevalence

Globally, from 10 April to 7 May 2023 (28 days), 27 992 SARS-CoV-2 sequences were shared through GISAID. WHO is currently monitoring two variants of interest (VOIs), XBB.1.5 and XBB.1.16, along with six variants under monitoring (VUMs) and their descendent lineages. The VUMs are BA.2.75, CH.1.1, BQ.1, XBB, XBB.1.9.1, and XBB.1.9.2. The variant XBF has been removed from the list of VUMs due to its declining prevalence (<1%) observed both globally and across WHO regions over the past four weeks.

There has been an increase in the number of countries reporting the VOIs. Between 20 March and 16 April 2023, 64 countries reported XBB.1.5 sequences, resulting in a cumulative total of 109 countries (Figure 4A, Table 2). During the same 28-day period, 34 countries reported XBB.1.16 sequences, bringing the cumulative total to 46 countries (Figure 4B, Table 2). While XBB.1.5 remains dominant globally, its prevalence has been declining steadily. In week 16 (17 to 23 April 2023), XBB.1.5 accounted for 47.5% of sequences, down from 52.4% in week 12 (20 to 26 March 2023). Globally, XBB.1.16 continues to rise in prevalence, accounting for 8.6% of sequences in week 16 compared to 4.0% in week 12.

Table 2 shows the number of countries reporting VOIs and VUMs, and their prevalence from week 12 to week 16. Among the VUMs, XBB, XBB.1.9.1 and XBB.1.9.2 have shown increasing trends. Conversely, other VUMs show declining trends during the same reporting period. The VOI and VUMs exhibiting increasing trends are highlighted in orange, while those with decreasing trends are highlighted in green.

Current SARS-CoV-2 variant trends differ across and within WHO regions and countries. Population immunity--from vaccination and previous SARS-CoV-2 infection--is among the factors contributing to the observed heterogeneity in the variant circulation dynamics.^{i,ii} The VOIs, XBB.1.5 and XBB.1.16, are dominant in four regions and one region, respectively: XBB.1.5 is dominant in the African, American, European, and Western Pacific Regions; XBB.1.16 is dominant in the South-East Asia region. The VUM XBB.1.9.1 is dominant in the Eastern Mediterranean Region (Figure 5).

The global trend of the number and percentage of SARS-CoV-2 sequences is shown in Figure 6. With the declining trends of testing and sequencing globally, the impact of emerging SARS-CoV-2 variants on disease severity remains unclear. Although there are currently no reported laboratory or country reports indicating an association between VOIs/VUMs and increased disease severity, low and unrepresentative levels of SARS-CoV-2 genomic surveillance continue to pose challenges in adequately assessing the SARS-CoV-2 variant landscape.

ⁱ SARS-CoV-2 variant biology: immune escape, transmission and fitness: https://www.nature.com/articles/s41579-022-00841-7

ⁱⁱ Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa: https://www.nature.com/articles/s41467-022-35652-0

Table 2. Weekly prevalence of SARS-CoV-2 VOIs and VUMs, week 12 to week 16 of 2023

Lineage	Countries	Sequences	2023-12	2023-13	2023-14	2023-15	2023-16
XBB.1.5* (VOI)	109	203 469	52.38	51.66	50.46	48.98	47.54
XBB.1.16* (VOI)	46	7153	4.01	4.98	6.64	7.73	8.58
BA.2.75*	121	109 754	3.70	3.39	3.46	3.15	1.51
CH.1.1*	91	44 419	4.88	4.92	3.89	3.92	3.57
BQ.1*	147	406 465	5.83	4.28	3.72	2.74	1.75
XBB*	124	61 726	4.92	5.59	5.94	7.14	8.20
XBB.1.9.1*	78	19 946	8.03	9.82	10.40	12.34	12.40
XBB.1.9.2*	53	4877	1.94	2.68	2.72	3.03	3.82
Unassigned	103	149 082	4.25	2.49	2.53	1.79	2.75
Other ⁺	207	6 704 771	4.39	5.67	6.25	6.76	8.47


* Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not include XBB.1.5, XBB.1.9.1, XBB.1.9.2 and XBB.1.16.

⁺ Others are other circulating lineages excluding the VOI, VUMs, BA.1*, BA.2*, BA.3*, BA.4*, BA.5*.

Figure 4. Global prevalence of XBB.1.5 and XBB.1.16, 20 March to 16 April 2023**

Α

В



*Reporting period to account for delay in sequence submission to GISAID.

*Historical presence indicates countries previously reporting XBB.1.5 sequences but that have not reported them within the period from 20 March to 16 April 2023.

Figure 5. Top three SARS-CoV-2 variants (including non-VOIs/VUMs) by WHO region, week 12 to week 16 of 2023





Figure 6. The number and percentage of SARS-CoV-2 sequences, from 1 October 2022 to 16 April 2023



Date of specimen collection

Figure 6. Panel A shows the number, and **Panel B** the percentage, of all circulating variants since October 2022. Omicron sister-lineages and additional Omicron VOC descendent lineages under further monitoring are shown. *BA.1*, BA.2*, BA.3*, BA.4* and BA.5** (* indicates inclusion of descendent lineages) include all BA.1, BA.2, BA.3, BA.4 and BA.5 pooled descendent lineages, except currently circulating variants shown individually. The *Unassigned* category includes lineages pending for a PANGO lineage name, whereas the *Other* category includes lineages that are assigned but not listed in the legend. Source: SARS- CoV-2 sequence data and metadata from GISAID, from 1 October 2022 to 16 April 2023.

Additional resources

- Tracking SARS-CoV-2 Variants
- WHO statement on updated tracking system on SARS-CoV-2 variants of concern and variants of interest
- WHO XBB.1.16 Initial Risk Assessment, 17 April 2023
- WHO XBB.1.5 rapid risk assessment, 24 February 2023

Vaccine effectiveness of primary series and booster vaccination against Omicron and its descendant lineages

Vaccine effectiveness

The Forest plots displaying the effectiveness of COVID-19 vaccines against Omicron and its descendant lineages are available on View-hub.org and are updated regularly (last updated on 8 May 2023). All data are collected as part of an ongoing systematic review of COVID-19 vaccine effectiveness (VE) studies (methods described here). COVID-19 VE results are summarized in the following plots, where data are available:

- VE of primary series and first booster dose by vaccine for all vaccines
- VE for various sub-populations of interest
- Absolute and relative VE of a second booster dose (for more information on interpreting relative VE, see the special focus on relative vaccine effectiveness from the 29 June 2022 Weekly Epidemiological Update)
- Duration of VE over time for vaccines
- Absolute VE of bivalent vaccines given as a first, second, or third booster dose

In summary, findings from COVID-19 VE studies show reduced VE of primary series vaccines against the Omicron variant for all outcomes (*severe disease, symptomatic disease*, and *infection*) compared to the original SARS-CoV-2 strain and the four previous VOCs (Alpha, Beta, Gamma, and Delta). Importantly though, VE estimates against the Omicron variant remain higher for *severe disease* than for other outcomes. VE of primary series vaccination against *symptomatic disease* and *infection* decreases rapidly over time. First booster vaccination, regardless of the vaccine used in the primary series, substantially improves VE for all outcomes, with VE declining more in the first six months after first booster vaccination for *symptomatic disease* and *infection* than it does for *severe disease*. VE of a second booster dose with a monovalent mRNA vaccine shows a similar pattern of improved VE followed by waning, as observed after the first booster dose.

Emerging evidence on mRNA bivalent vaccines, which contain both the ancestral strain and the Omicron strain, indicates that a bivalent vaccine administered as a first, second, or third booster dose improves protection against *symptomatic disease* and *severe disease* compared to unvaccinated persons. Additionally, persons receiving a bivalent vaccine as a second or third booster dose have additional protection compared to persons who received a monovalent mRNA vaccine as a first or second booster dose in the past. However, comparing bivalent and monovalent boosters directly in observational VE studies has proven challenging due to potential time-related confounding (e.g., time since last vaccine dose, subvariant circulation, incidence rates). A few recent studies have evaluated protection of bivalent and monovalent boosters during the same time period; two studies (United Kingdom, France) have shown marginal (approximately 10%) higher VE for bivalent vaccines against Omicron infection; one study from Canada showed no difference in VE between monovalent and bivalent vaccines against hospitalization.

Neutralization

Neutralizing antibody studies can provide early insights into vaccine performance against new and emerging variants. For more information on the neutralization capacity of COVID-19 vaccines against Omicron sub-variants, please see a recent systematic review of post-monovalent vaccination neutralization responses to Omicron BA.1, BA.2, BA.3, and BA.4/BA.5. In addition, neutralization plots displaying the results of a living systematic review of neutralization studies are updated regularly on VIEW-hub.org (last updated on 5 May 2023) and contain information on more recent Omicron descendant lineages, such as BQ.1 and XBB.


The totality of the evidence to date suggests that neutralizing antibody response of first booster vaccination against Omicron BA.1 is approximately six-fold lower compared to the ancestral strain, which represents a greater reduction than observed with previous VOCs. The median fold-reduction in geometric mean titers is also two times lower for BA.4/BA.5 relative to BA.1. A recent report suggests that VE against BA.4/BA.5 is likely lower than against BA.1, possibly due to lower neutralization titers, although the results may also be due to methodological factors relating to how the VE studies were performed. Early evidence suggests further reductions in neutralization capacity against the new subvariants BQ.1/BQ.1.1 and XBB/XBB.1/XBB.1.5. Primary series neutralization against Omicron (without a booster) was insufficient to accurately compare neutralization reductions for recent lineages.

Finally, a summary of neutralization responses comparing monovalent to bivalent mRNA vaccines is also available on VIEW-hub.org, providing preliminary evidence of improved performance of bivalent vaccines against more recent Omicron descendant lineages.

WHO regional overviews Data for 10 April to 7 May 2023 African Region

The African Region reported 7408 new cases in the last 28 days, a 25% decrease as compared to the previous 28-day period. Nine (18%) of the 50 countries for which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Cabo Verde (335 vs 33 new cases; +915%), Mayotte (19 vs four new cases; +375%), and the Democratic Republic of the Congo (459 vs 130 new cases; +253%). The highest numbers of new cases were reported from Mauritius (4596 new cases; 361.4 new cases per 100 000; +235%), the Democratic Republic of the Congo (459 new cases; <1 new case per 100 000; +253%), and Cabo Verde (335 new cases; 60.3 new cases per 100 000; +915%).

The number of new 28-day deaths in the Region decreased by 50% as compared to the previous 28-day period, with 12 new deaths reported. The highest numbers of new deaths were reported from Mauritius (four new deaths; <1 new death per 100 000; no deaths reported the previous 28-day period), Zimbabwe (two new deaths; <1 new death per 100 000; -83%), and Cameroon (one new death; <1 new death per 100 000; -50%).




Updates from the African Region

Region of the Americas

The Region of the Americas reported over 647 000 new cases in the last 28 days, a 35% decrease as compared to the previous 28-day period. Seventeen (30%) of the 56 countries for which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Saint Lucia (24 vs two new cases; +1100%), Turks and Caicos Islands (23 vs four new cases; +475%), and Grenada (10 vs three new cases; +233%). The highest numbers of new cases were reported from the United States of America (366 173 new cases; 110.6 new cases per 100 000; -35%), Brazil (168 717 new cases; 79.4 new cases per 100 000; -28%), and Mexico (34 058 new cases; 26.4 new cases per 100 000; -40%).

The number of new 28-day deaths in the Region increased by 9% as compared to the previous 28-day period, with 7483 new deaths reported. The highest numbers of new deaths were reported from the United States of America (4680 new deaths; 1.4 new deaths per 100 000; -36%), Brazil (1277 new deaths; <1 new death per 100 000; +2%), and Canada (508 new deaths; 1.3 new deaths per 100 000; -16%).




Updates from the <u>Region of the Americas</u>

Eastern Mediterranean Region

The Eastern Mediterranean Region reported over 40 000 new cases in the last 28 days, a 24% decrease as compared to the previous 28-day period. Three (14%) of the 22 countries for which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Morocco (1099 vs 207 new cases; +431%), Afghanistan (5244 vs 2002 new cases; +162%), and Qatar (7895 vs 6455 new cases; +22%). The highest numbers of new cases were reported from the Islamic Republic of Iran (12 023 new cases; 14.3 new cases per 100 000; -51%), Qatar (7895 new cases; 274 new cases per 100 000; +22%), and Saudi Arabia (5273 new cases; 15.1 new cases per 100 000; -12%).

The number of new 28-day deaths in the Region increased by 1% as compared to the previous 28-day period, with 707 new deaths reported. The highest numbers of new deaths were reported from the Islamic Republic of Iran (595 new deaths; 0.7 new deaths per 100 000; similar with the previous 28-day), Tunisia (35 new deaths; <1 new death per 100 000; +59%), and Lebanon (28 new deaths; <1 new death per 100 000; -22%).




Updates from the Eastern Mediterranean Region

European Region

The European Region reported over 800 000 new cases in the last 28 days, a 38% decrease as compared to the previous 28-day period. Six (10%) of the 61 countries for which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Spain (47 078 vs 20 280 new cases; +132%), Andorra (76 vs 41 new cases; +85%), and Sweden (4471 vs 3006 new cases; +49%). The highest numbers of new cases were reported from France (173 375 new cases; 266.6 new cases per 100 000; -19%), the Russian Federation (163 661 new cases; 112.1 new cases per 100 000; -44%), and Italy (88 154 new cases; 147.8 new cases per 100 000; +2%).

The number of new 28-day deaths in the Region decreased by 41% as compared to the previous 28-day period, with 6345 new deaths reported. The highest numbers of new deaths were reported from the Russian Federation (955 new deaths; <1 new death per 100 000; -3%), France (944 new deaths; 1.5 new deaths per 100 000; +39%), and Spain (694 new deaths; 1.5 new deaths per 100 000; +60%).




Updates from the European Region

South-East Asia Region

The South-East Asia Region reported over 258 000 new cases in the last 28 days, a 223% increase as compared to the previous 28-day period. Ten (91%) of the 11 countries for which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Myanmar (1933 vs 143 new cases; +1252%), Thailand (5033 vs 663 new cases; +659%), and the Maldives (632 vs 150 new cases; +321%). The highest numbers of new cases were reported from India (213 014 new cases; 15.4 new cases per 100 000; +222%), Indonesia (36 186 new cases; 13.2 new cases per 100 000; +659%).

The number of new 28-day deaths in the Region increased by 281% as compared to the previous 28-day period, with 1178 new deaths reported. The highest numbers of new deaths were reported from India (715 new deaths; <1 new death per 100 000; +289%), Indonesia (407 new deaths; <1 new death per 100 000; +291%), and Thailand (27 new deaths; <1 new death per 100 000; +69%).




Updates from the South-East Asia Region

Western Pacific Region

The Western Pacific Region reported over 975 000 new cases in the last 28 days, a 35% increase as compared to the previous 28-day period. Fourteen (40%) of the 35 countries for which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Viet Nam (46 230 vs 664 new cases; +6862%), Mongolia (118 vs 13 new cases; +808%), and the Lao People's Democratic Republic (48 vs 14 new cases; +243%). The highest numbers of new cases were reported from the Republic of Korea (363 691 new cases; 709.4 new cases per 100 000; +32%), Japan (262 145 new cases; 207.3 new cases per 100 000; +36%), and Australia (114 460 new cases; 448.9 new cases per 100 000; +51%).

The number of new 28-day deaths in the Region decreased by 33% as compared to the previous 28-day period, with 1387 new deaths reported. The highest numbers of new deaths were reported from Japan (564 new deaths; <1 new death per 100 000; -36%), Australia (315 new deaths; 1.2 new deaths per 100 000; +23%), and the Republic of Korea (210 new deaths; <1 new death per 100 000; +4%).



Updates from the Western Pacific Region

Hospitalizations and ICU admissions

At the global level, during the past 28 days (3 April to 30 April 2023), a total of 109 546 new hospitalizations and 2834 new intensive care unit (ICU) admissions were reported (Figure 8). This represents a 29% and 4% decrease in new hospitalizations and in ICU admissions, respectively, compared to the previous 28 days (6 March 2 April 2023). The presented hospitalization data are preliminary and might change as new data become available. Furthermore, hospitalization data are subject to reporting delays. These data also likely include both hospitalizations with incidental cases of SARS-CoV-2 infection and those due to COVID-19 disease.

Globally, during the past 28 days, 46 (20%) countries reported data to WHO on new hospitalizations at least once (Figure 7). The European Region had the highest proportion of countries reporting data on new hospitalizations (22 countries; 36%), followed by the South-East Asia Region (three countries; 27%), the African Region (eight countries; 16%), the Eastern Mediterranean Region (three countries; 14%), the Region of the Americas (seven countries; 13%), and the Western Pacific Region (three countries; 9%). The proportion of countries that consistentlyⁱⁱⁱ reported new hospitalizations for the period was 10% (23 countries).

Among the 23 countries consistently reporting new hospitalizations, four (17%) countries registered an increase of 20% or greater in hospitalizations during the past 28 days compared to the previous 28-day period: Mongolia (117 vs 12; +875%), Afghanistan (67 vs 8; +738%), Indonesia (6091 vs 1732; +252%), and Singapore (2078 vs 984; +111%). The highest number of new hospitalizations was reported from the United States of America (49 384 vs 70 898; -30%), Ukraine (13 380 vs 17 195; -22%) and France (11 373 vs 9995; +14%).

Across the six WHO regions, in the past 28 days, a total of 38 (16%) countries reported data to WHO on new ICU admissions at least once (Figure 7). The European Region had the highest proportion of countries reporting data on new ICU admissions (18 countries; 30%), followed by the Eastern Mediterranean Region (five countries; 23%), the South-East Asia Region (two countries; 18%), the Western Pacific Region (five countries; 14%), the Region of the Americas (six countries; 11%), and the African Region (two countries; 4%). The proportion of countries that consistently ⁱⁱⁱ reported new ICU admissions for the period was 9% (20 countries).

Among the 20 countries consistently ⁱⁱⁱ reporting new ICU admissions, six (30%) countries showed an increase of 20% or greater in new ICU admissions during the past 28 days compared to the previous 28-day period: Indonesia (262 vs 103; +154%), Singapore (47 vs 24; +96%), Sweden (48 vs 31; +55%), France (1127 vs 881; +28%), Australia (260 vs 211; +23%), and Latvia (42 vs 35; +20%). The highest numbers of new ICU admissions were reported from France (1127 vs 881; +28%), Ukraine (391 vs 450; -13%), and Indonesia (262 vs 103; +154%).

ⁱⁱⁱ "Consistently" as used here refers to countries that submitted data for new hospitalizations and intensive care unit admissions for the four consecutive weeks that make up the 28-day period.





Figure 7. Weekly proportion of countries reporting new hospitalizations and ICU admissions: epidemiological week 1, 2020 to week 17, 2023

Note: Recent weeks are subject to reporting delays and should not be interpreted as a declining trend.

Figure 8. COVID-19 cases, deaths, hospitalizations, and ICU admissions reported weekly to WHO, as of 30 April 2023



GLOBAL COVID -19 WEEKLY HOSPITAL ADMISSION

Note: Recent weeks are subject to reporting delays and should not be interpreted as a declining trend. Source: WHO Detailed Surveillance Dashboard

Summary of the Monthly Operational Update

The Monthly Operational Update is a report provided by the COVID-19 Strategic Preparedness and Response Plan (SPRP) monitoring and evaluation team, which aims to update on the ongoing global progress against the COVID-19 SPRP 2021 framework. In this edition, highlights of country-level actions and WHO support to countries for COVID-19 and other respiratory diseases include:

- The Eastern Mediterranean Region holds its third Scientific Conference and sixth EMARIS meeting on acute respiratory infections
- Strengthening influenza preparedness through an OpenWHO online course
- Mobile health caravans rally the western Balkans to COVID-19 vaccination, bringing health advice closer to where people are
- Assessing the quality of laboratory testing for SARS-CoV-2 through external quality assessments (EQA)
- WHO Global Influenza Surveillance and Response System (GISRS) External Quality Assessment Programme 2022 for molecular detection of SARS-CoV-2
- A global analysis of COVID-19 intra-action reviews: Reflecting on, adjusting and improving emergency preparedness and response during a pandemic examples from the European Region

Fifteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the COVID-19 pandemic

The fifteenth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the COVID-19 pandemic was held on 4 May 2023. During the deliberative session, the Committee members highlighted the decreasing trend in COVID-19 deaths, the decline in COVID-19 related hospitalizations and ICU admissions, and the high levels of population immunity to SARS-CoV-2. While acknowledging the remaining uncertainties posed by potential evolution of SARS-CoV-2, they advised the WHO Director-General that it is time to transition to the long-term management of the COVID-19 pandemic.

The WHO Director-General concurred with the advice offered by the Committee regarding the ongoing COVID-19 pandemic. He determined that COVID-19 is now an established and ongoing health issue, which no longer constitutes a public health emergency of international concern (PHEIC).

The WHO Director-General considered the advice provided by the Committee and issued a series of Temporary Recommendations. The WHO Director-General will convene an IHR Review Committee to advise on Standing Recommendations for the long-term management of the SARS-CoV-2 pandemic, taking into account the 2023-2025 COVID-19 Strategic Preparedness and Response Plan. During this transition, States Parties are advised to continue following the issued Temporary Recommendations.

The Temporary Recommendations issued by the WHO Director-General to all States Parties, as well as the full statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic, are available on the WHO website.

Statement of the 15th IHR Emergency Committee on COVID-19 WHO Director-General's announcement of the decision

Annex 1. Data, table, and figure notes

Data presented are based on official laboratory-confirmed COVID-19 cases and deaths reported to WHO by country/territories/areas, largely based upon WHO case definitions and surveillance guidance. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change, and caution must be taken when interpreting these data as several factors influence the counts presented, with variable underestimation of true case and death incidences, and variable delays to reflecting these data at the global level. Case detection, inclusion criteria, testing strategies, reporting practices, and data cut-off and lag times differ between countries/territories/areas. A small number of countries/ territories/areas report combined probable and laboratory-confirmed cases. Differences are to be expected between information products published by WHO, national public health authorities, and other sources.

A record of historic data adjustment made is available upon request by emailing epi-data-support@who.int. Please specify the countries of interest, time period, and purpose of the request/intended usage. Prior situation reports will not be edited; see covid19.who.int for the most up-to-date data. COVID-19 confirmed cases and deaths reported in the last seven days by countries, territories, and areas, and WHO Region (reported in previous issues) are now available at: https://covid19.who.int/table.

'Countries' may refer to countries, territories, areas or other jurisdictions of similar status. The designations employed, and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Countries, territories, and areas are arranged under the administering WHO region. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

Updates on the COVID-19 outbreak in the Democratic People's Republic of Korea are not included in this report as the number of laboratory-confirmed COVID-19 cases is not reported.

Annex 2. SARS-CoV-2 variants assessment and classification

WHO, in collaboration with national authorities, institutions and researchers, routinely assesses if variants of SARS-CoV-2 alter transmission or disease characteristics, or impact the effectiveness of vaccines, therapeutics, diagnostics or public health and social measures (PHSM) applied to control disease spread. Potential variants of concern (VOCs), variants of interest (VOIs) or variants under monitoring (VUMs) are regularly assessed based on the risk posed to global public health.

The classifications of variants will be revised as needed to reflect the continuous evolution of circulating variants and their changing epidemiology. Criteria for variant classification, and the lists of currently circulating and previously circulating VOCs, VOIs and VUMs, are available on the WHO Tracking SARS-CoV-2 variants website. National authorities may choose to designate other variants and are strongly encouraged to investigate and report newly emerging variants and their impact.

WHO continues to monitor all SARS-CoV-2 variants and to track changes in prevalence and viral characteristics. The current trends describing the circulation of variants should be interpreted with due consideration of the limitations of the COVID-19 surveillance systems. These include differences in sequencing capacity and sampling strategies between countries, changes in sampling strategies over time, reductions in tests conducted and sequences shared by countries, and delays in uploading sequence data to GISAID.⁵

References

- Cohen C, Kleynhans J, von Gottberg A, et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21. *The Lancet Infectious Diseases*. 2022;22(6):821-834. doi:10.1016/S1473-3099(22)00069-X
- 2. Coronavirus (COVID-19) Infection Survey, UK: 4 November 2022 Office for National Statistics. Accessed November 21, 2022. https://www.ons.gov.uk/releases/coronaviruscovid19infectionsurveyuk4november2022
- 3. Parikh S, O'Laughlin K, Ehrlich HY, et al. Point Prevalence Testing of Residents for SARS-CoV-2 in a Subset of Connecticut Nursing Homes. *JAMA*. 2020;324(11):1101-1103. doi:10.1001/jama.2020.14984
- 4. Real-time dashboard. Coronavirus disease 2019. Accessed November 15, 2022. https://covid19.sph.hku.hk/dashboard
- 5. Chen Z, Azman AS, Chen X, et al. Global landscape of SARS-CoV-2 genomic surveillance and data sharing. *Nature genetics*. 2022;54(4). doi:10.1038/s41588-022-01033-y